Literature DB >> 21118936

Humoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area.

Felicitat Todolí1, Laia Solano-Gallego, Rafael de Juan, Pere Morell, Maria Del Carmen Núñez, Rodrigo Lasa, Silvia Gómez-Sebastián, José M Escribano, Jordi Alberola, Alhelí Rodríguez-Cortés.   

Abstract

Leishmania infantum causes visceral leishmaniasis, a severe zoonotic and systemic disease that is fatal if left untreated. Identification of the antigens involved in Leishmania-specific protective immune response is a research priority for the development of effective control measures. For this purpose, we evaluated, in 27 dogs from an enzootic zone, specific humoral and cellular immune response by delayed-type hypersensitivity (DTH) skin test both against total L. infantum antigen and the raw Trichoplusia ni insect-derived kinetoplastid membrane protein-11 (rKMPII), tryparedoxin peroxidase (rTRYP), Leishmania homologue of receptors for activated C kinase (rLACK), and 22-kDa potentially aggravating protein of Leishmania (rpapLe22) antigens from this parasite. rTRYP induced the highest number of positive DTH responses (55% of leishmanin skin test [LST]-positive dogs), showing that TRYP antigen is an important T cell immunogen, and it could be a promising vaccine candidate against this disease. When TRYP-DTH and KMPII-DTH tests were evaluated in parallel, 82% of LST-positive dogs were detected, suggesting that both antigens could be considered as components of a standardized DTH immunodiagnostic tool for dogs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21118936      PMCID: PMC2990046          DOI: 10.4269/ajtmh.2010.09-0784

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  66 in total

Review 1.  Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania.

Authors:  P Holzmuller; R Bras-Gonçalves; J-L Lemesre
Journal:  Parasitology       Date:  2006       Impact factor: 3.234

2.  Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV.

Authors:  D M Pérez-Filgueira; P Resino-Talaván; C Cubillos; I Angulo; M G Barderas; J Barcena; J M Escribano
Journal:  Virology       Date:  2007-04-16       Impact factor: 3.616

3.  Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis.

Authors:  Katie M Kurkjian; Aida J Mahmutovic; Kathryn L Kellar; Rashidul Haque; Caryn Bern; W Evan Secor
Journal:  Cytometry A       Date:  2006-05       Impact factor: 4.355

4.  Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study.

Authors:  Eltahir Awad Gasim Khalil; Ahmed Mudawi Musa; Farroukh Modabber; Ahmed Mohamed El-Hassan
Journal:  Ann Trop Paediatr       Date:  2006-12

5.  Leishmania-specific isotype levels and their relationship with specific cell-mediated immunity parameters in canine leishmaniasis.

Authors:  Alhelí Rodríguez-Cortés; Hugo Fernández-Bellón; Antonio Ramis; Lluís Ferrer; Jordi Alberola; Laia Solano-Gallego
Journal:  Vet Immunol Immunopathol       Date:  2007-01-31       Impact factor: 2.046

6.  A long term experimental study of canine visceral leishmaniasis.

Authors:  Alhelí Rodríguez-Cortés; Ana Ojeda; Laura López-Fuertes; Marcos Timón; Laura Altet; Laia Solano-Gallego; Elisenda Sánchez-Robert; Olga Francino; Jordi Alberola
Journal:  Int J Parasitol       Date:  2006-12-14       Impact factor: 3.981

7.  Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis.

Authors:  M Kemp; J A Kurtzhals; K Bendtzen; L K Poulsen; M B Hansen; D K Koech; A Kharazmi; T G Theander
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum.

Authors:  E Pinelli; R Killick-Kendrick; J Wagenaar; W Bernadina; G del Real; J Ruitenberg
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

9.  Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

Authors:  O Francino; L Altet; E Sánchez-Robert; A Rodriguez; L Solano-Gallego; J Alberola; L Ferrer; A Sánchez; X Roura
Journal:  Vet Parasitol       Date:  2006-02-13       Impact factor: 2.738

10.  Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.

Authors:  Arlene Caldas; Cecília Favali; Dorlene Aquino; Vera Vinhas; Johan van Weyenbergh; Cláudia Brodskyn; Jackson Costa; Manoel Barral-Netto; Aldina Barral
Journal:  BMC Infect Dis       Date:  2005-12-19       Impact factor: 3.090

View more
  2 in total

1.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

2.  Design, Construction and Immunogenicity Assessment of pEGFP-N1-KMP11-GP96 (Fusion) as a DNA Vaccine Candidate against Leishmania major Infection in BALB/c Mice.

Authors:  Abdolhossein Dalimi; Vahid Nasiri
Journal:  Iran J Parasitol       Date:  2020 Jan-Mar       Impact factor: 1.012

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.